All Posts Tagged With: "CMC"
(CMC) Company News for December 20, 2011 – Corporate Summary
• In a deal worth $560 million, Winn-Dixie Stores Inc. (NASDAQ:WINN) will be sold to supermarket operator Bi-Lo LLC. Following the development, shares of Winn-Dixie soared 70.1% • A company spokeswoman told Reuters that Procter & Gamble Co. (NYSE:PG) has stopped...
20Dec2011 | vitalstocks | 0 comments | Continued(AMLN) Amylin Pharmaceuticals Loss Narrows on Lower Costs
Amylin Pharmaceuticals (AMLN) reported a net loss of 21 cents per share in the second quarter of 2011, a penny wider than the Zacks Consensus Estimate but well below the year-ago loss of 28 cents. Despite a decline in revenues, year-over-year loss declined due to lower expenses. Second...
27Jul2011 | vitalstocks | 0 comments | Continued(GE) General Electric Aviation Gets Orders Worth $27 Billion
GE Aviation, a part of General Electric (GE) and Nexcelle have signed an agreement whereby Nexcelle’s nacelle system (a streamlined enclosure on an aircraft that provides shelter to the crew, cargo and the engine) will be included in the GE Passport 20 jet engine. This agreement...
29Jun2011 | vitalstocks | 0 comments | Continued(AKS) Stock Market News for April 20, 2011 – Market News
On Tuesday, markets ended with modest gains as an earnings-driven trading day witnessed positive results and sentiments were boosted by strong results from bellwether stocks. Earnings reports of healthcare stocks helped push the markets higher aided by steel stocks. Tech majors...
20Apr2011 | vitalstocks | 0 comments | Continued(AMLN) Amylin Pharmaceuticals Reports Earnings Loss In-Line with Estimates
Amylin Pharmaceuticals (AMLN) reported a net loss of 24 cents per share in the first quarter of 2011, in line with the Zacks Consensus Estimate and 3 cents below the year-ago loss of 27 cents. Despite a decline in revenues, year-over-year loss declined due to lower expenses. First...
20Apr2011 | vitalstocks | 0 comments | Continued(AMLN) Amylin Pharmaceuticals Analyst Reports Neutral on Shares
We recently reiterated our Neutral recommendation on Amylin Pharmaceuticals, Inc. (AMLN). The company reported a net loss of $0.94 per share in 2010, narrower than the Zacks Consensus Estimate of $1.26 and the year-ago loss of $1.20. Full year revenues came in at $668.8 million,...
29Mar2011 | vitalstocks | 0 comments | Continued(PLX) Protalix BioTherapeutics Sees FDA Setback for Gaucher Drug
Protalix BioTherapeutics, Inc. (PLX) was dealt a huge blow recently with the US Food and Drug Administration (FDA) issuing a complete response letter (CRL) for the company’s Gaucher disease candidate, taliglucerase alfa. FDA Requests Additional Information The FDA asked the...
4Mar2011 | vitalstocks | 0 comments | Continued(NUE) Nucor Provides Guidance – Analyst Raises Estimates
Nucor Corporation (NUE) provided its first quarter 2010 earnings update, indicating it expected earnings per share to be in the range of a loss of 5 cents to earnings of 5 cents per share. The Zacks Consensus Estimate is pegged at net earnings of 2 cents in the first quarter....
18Mar2010 | vitalstocks | 0 comments | Continued(GGB) Gerdau S.A. Margins Recovered
Today, Gerdau S.A. (GGB) announced consolidated results for the third quarter of 2009. The company did not provide comparable year-on-year figures in a securities filing. Sales reached 3.9 million tons in the quarter, 15% higher than in the second quarter of 2009, reflecting...
7Nov2009 | vitalstocks | 0 comments | Continued